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Advancements in antiretroviral therapy have drastically increased the life expectancy for those infected with HIV. Today, a new
subgroup of older patients with long-term controlledHIV exists, and its populace is continuouslymounting.Therefore, it is essential
to understand the enduring effects of chronic suppressed HIV infection in order to further improve HIV management in these
patients. This paper will examine the role of HIV in chronic inflammation and immune dysfunction, the dynamic interaction that
exists between comorbidity and HIV, and the potential consequences of long-term antiretroviral therapy in an effort to provide the
best management options for the virally suppressed HIV patient.
1. Introduction
Before the advent of effective cART, HIV infection was
usually a death sentence. The virus would hijack the immune
system unchecked, often leading to full-blown AIDS and
acute opportunistic infection. According to the CDC, there
were a total of 774,467 diagnosed cases of AIDS and 448,060
AIDS-related deaths in the USA from 1981 to 2000 [1]. Over
the past two decades, cART has dramatically reduced the
incidence ofmorbidity andmortality related to bothHIV and
opportunistic infections. These advancements have enabled
most persons living with HIV (PLWH) to achieve an unde-
tectable viral load (VL) within 12 weeks of the initiation
of treatment. This has led to the emergence of a new and
growing population of aging HIV-positive patients. The
effects of chronic suppressed HIV infection in this group
are only beginning to become understood, and methods to
combat these effects are poorly studied.
Although the average life expectancy for PLWH has
increased significantly, it is still slightly less than that of the
general population.The highest estimated life expectancy for
a newly diagnosedHIV-positive 20-year-old patient on cART
in the USA or Canada is just above 70 years [2]. Reasons
for this gap have become a new focus of HIV research. One
theory is that even with undetectable VL and adequate CD4+
count there exists a state of persistent inflammation. Also,
traditional comorbidities may become worsened by chronic
HIV infection. Furthermore, long-termuse of cARTmay lead
to adverse effects that could further augment the severity
of these comorbidities. This paper will focus on each one
of these concepts in order to provide possible treatment
measures to thwart their harmful effects on patients with
suppressed HIV infection.
2. Materials and Methods
A computer-based search using Pubmed and Embase was
conducted to review the literature regarding antiretroviral
interventions to decrease chronic inflammation in patients
on combination antiretroviral therapy (cART).
3. Results and Discussion
3.1. Inflammation and Dysregulation of the Immune System.
Inflammatory markers appear to directly correlate with
morbidity and mortality in patients infected with HIV. Since
Hindawi Publishing Corporation
BioMed Research International
Volume 2016, Article ID 3420638, 12 pages
http://dx.doi.org/10.1155/2016/3420638
2 BioMed Research International
Chronic inflammation T-cell activation
Microbial translocation
Low-grade/intermittent viremia cART adverse events
Immune dysregulation relationship to comorbidities
 in patients with HIV
Traditional comorbidity
(smoking, obesity, metabolic syndrome, etc.)
Coinfection
(HCV, HPV, HHV8, CMV, etc.)
Figure 1:Microbial translocation, low-grade viremia, coinfection, and adverse events from cARTall contribute towards chronic inflammation
and T-cell activation. This immune dysfunction augments the severity of traditional comorbid conditions. Furthermore, the comorbidities
themselves intensify all of the aforementioned factors causing a positive feedback cycle.
this inflammatory process, which is a correlate of T-cell
activation, is much more pronounced when the virus is not
suppressed, the discussion will be limited towards patients
receiving effective treatment forHIV [3]. Although successful
cART does not suppress all inflammatory mechanisms asso-
ciated with HIV, it has been shown to decrease some immune
activationmarkers to the level ofHIV-uninfected individuals,
particularly monocyte-macrophage activation [4]. However,
in clinical practice HIV virus load (VL) ismeasured intermit-
tently and there are different cut-offs for detection. Thus, it is
conceivable that low-grade or intermittent viremia is actually
occurring in patients that are classified as undetectable. This
phenomenon could play a role in persistent inflammation.
It is also relatively well established that a chronic inflam-
matory state in patients receiving appropriate cART is
primarily related to the extent of damaged gut-associated
lymphoid tissue and its subsequent microbial translocation
[5, 6]. This process involves commensal microbes from the
gastrointestinal tract entering portal and systemic circulation
[7]. Acute HIV infection is marked by an intense surge of
cytokines such as interferon-𝛼, interferon-𝛾, tumor necrosis
factor, and IL-6 which leads to immune activation and severe
inflammatory reaction [8]. This causes a profound depletion
of CD4+ cells from the gut, which only partially improves
with effective cART [9, 10]. This explains the reasoning
behind intestinal microbial translocation and subsequent
immune stimulation [11]. One method for studying micro-
bial translocation is through the measurement of serum
lipopolysaccharide (LPS). The SMART study revealed that
soluble CD14, a marker of monocyte response to LPS, was
an independent predictor of mortality in PLWH [12]. This
was corroborated by another case-control study by Hunt et
al., which concluded that gut epithelial barrier dysfunction
independently predicts mortality in individuals with treated
HIV infection who also have a history of AIDS [13].
Another factor relating to inflammation in PLWH is T-
cell function. It is unclear if immune dysregulation leads to
inflammation or vice versa. Nonetheless, they are usually
present together and both contribute to the burden of
comorbid illnesses [14]. Hunt et al. studied the relationship
of immune activation and increased CD4 count when HIV
was suppressed with cART and found that increased T-
cell activation was associated with shorter duration of viral
suppression, HCV coinfection, frequent low-level viremia,
lower nadir CD4+ T-cell counts, and a lower gain in CD4+
T-cells [15]. In an elegant study of impaired gut junctional
complexes by Tincati et al., a relationship was established
between gut damage, HIV viral reservoir, and CD4+ response
to cART [5]. They concluded that the more damage to the
gut and the larger the reservoir, the less the increase in
CD4+ cells while on suppressive cART [5]. Figure 1 illustrates
the factors involved in the chronic inflammatory state and
immune dysfunction in PLWH with controlled viral load.
It is also postulated that coinfection is a key contrib-
utor to immune dysregulation present in PLWH receiving
suppressive cART. This association was well established
by Masia´ et al., who prospectively studied multiple blood
biomarkers of inflammation in monoinfected HIV patients
compared to those coinfected with HHV8 [16]. Both groups
had a suppressed HIV VL, but inflammation and immune
activation were significantly higher in those with HHV8
coinfection [16]. Since HCV is another prevalent virus found
in 20–25% of PLWH, it is relevant to study its impact on
immune recovery as well. Zaegel-Faucher et al. retrospec-
tively reviewed this data in patients with undetectable VL
for at least 3 years and concluded that CD4+ percentage and
CD4/CD8 ratio were lower in patients coinfected with HCV
compared to those with monoinfection, even though they
had similar cART regimen and CD4+ and CD8+ counts at
first undetectable HIV VL [6]. Furthermore, Modjarrad and
Vermund reviewed the literature up to April 2010 and found
that treatment of Mycobacterium tuberculosis, syphilis, and
other infections significantly decreased HIV VL, even when
no cART was used [17]. In another prospective study using
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CMV PCR, Deayton et al. established a direct correlation of
positive PCR findings with newAIDS-defining disorders and
mortality in PLWH in the highly active cART era [18]. Lastly,
in their review of CMV in PLWH, Barrett et al. summarized
the evidence that CMV could be an important cofactor in the
development of age-relatedmorbidities inHIV infection [19].
The pivotal SMART trial provided strong evidence of
the association of inflammatory biomarkers and coagulation
with increased risk of all-cause mortality [20]. The study
also showed that interleukin-6 (IL-6) and D-dimer were
significantly associated with increased risk of CVD and other
causes of death, even in patients on cART [21]. Tenorio
et al. conducted a case-control study that concurred with
these findings, concluding that soluble inflammatorymarkers
correlated with non-AIDS-defining events in patients virally
suppressed on therapy [22].
3.2.The Role of Traditional Comorbidity and Coinfection. The
new challenges facing the HIV-infected population are non-
AIDS-related conditions. A prospective HIV cohort study by
the D:A:D group found that themost common comorbidities
leading to death in HIV patients were non-AIDS cancers,
cardiovascular disease (CVD), and liver disease [23]. Morlat
et al. expressed these same findings in a study in France in
2010 [24]. A Swiss HIV cohort study by Hasse et al. revealed
that stroke, myocardial infarction, diabetes mellitus (DM),
fragility bone fractures, and non-AIDS-defining malignan-
cies were significantly elevated for persons aged ≥65 years
[25]. Guaraldi et al. performed a case-control study on cART-
experienced patients treated atModenaUniversity, Italy, from
2002 to 2009 [26]. They were compared with age-, sex-, and
race-matched adults from the general population [26]. They
specifically looked at noninfectious comorbidities (NICMs),
which included CVD, hypertension, diabetes mellitus (DM),
bone fractures, and renal failure [26]. The study defined
polypathology (Pp) as the concurrent presence of ≥2 NICMs
and concluded that the prevalence of Pp among HIV patients
aged 41–50 years was similar to that among controls aged
51–60 years [26]. Logistic regression models showed that
independent predictors of Pp in the overall cohort were age
(odds ratioOR, 1.11), male sex (OR, 1.77), nadir CD4+ count<
200 cells/𝜇L (OR, 4.46), and cART exposure (OR, 1.01) [26].
Multiple studies have identified HIV as an independent
risk factor for acute myocardial infarction (AMI). Freiberg
et al. reviewed data from participants in the Veterans Aging
Cohort Study that included both HIV-infected and nonin-
fected individuals [27]. This study concluded that infection
with HIV was associated with a 50% increased risk of AMI
beyond which was explained by recognized risk factors [27].
In two cohorts from the Partners HealthCare System in
Boston, Triant et al. compared the rate of AMI in HIV-
positive and HIV-negative patients while adjusting for age,
gender, race, hypertension, DM, and dyslipidemia [28].They,
too, concluded that there was an increased risk of AMI in
patients with HIV, especially in HIV-positive women [28].
Lastly, Okeke et al. reviewed the hospital discharge data
from the Nationwide Inpatient Sample from 2002 to 2012
looking specifically for patients with AMI or stroke [29].
They used multivariable logistic regression to evaluate the
association between HIV and in-hospital death [29]. They
found that patients with a history of AIDS were significantly
more likely to die in-hospital after AMI and stroke than
noninfected patients [29]. This disparity was not observed
when infected patients without a history of AIDS were
compared to noninfected patients [29].
Malignancies that are considered AIDS-related such as
Kaposi’s sarcoma, primary central nervous system lym-
phoma, and cervical cancer have dramatically declined since
the advent of suppressive ART [30]. Furthermore, the inci-
dence of non-AIDS-related malignancies (NARM) including
anal cancer, hepatocellular carcinoma, head and neck can-
cers, lung cancers, non-Hodgkin’s lymphoma, andmelanoma
has increased so significantly that they now represent one of
the most common causes of death in PLWH in the USA [31].
Immune dysregulation and chronic inflammation in PLWH
can promote increased cell proliferation and generate poten-
tially damaging reactive oxygen species [32]. The immune
dysfunction associated with HIV infection may also lead to
impaired immune surveillance with an impaired ability to
both detect and eliminate early tumor cells [33]. Powles et
al. reported from their large prospective cohort that a nadir
CD4+ count < 200/microL had a significant association with
NARM [34]. Certain traditional risk factors for NARM are
more prevalent in PLWH [35, 36]. Some of these include
smoking, with its subsequent increase in lung cancer, as
well as hepatitis B and C viruses, with their associated risk
for hepatocellular carcinoma [35, 36]. There is a higher
incidence of Hodgkin’s lymphoma in PLWH than the general
population, and it is often associated with EBV coinfection
[37]. Probably the highest increase in cancer types in HIV-
infected patients compared to those that are noninfected
is related to HPV [38]. Associated cancer types with this
coinfection include anal cancer, head and neck cancer, and
cervical cancer (which is an AIDS-related malignancy) [38].
The incidence of DM is also increased in PLWH [39].
Inflammation and HIV lipodystrophy involve adipose tissue
redistribution, mitochondrial dysfunction, altered differen-
tiation of adipocytes, and increased adipocyte lipolysis [40,
41]. This leads to altered adipokine secretion, as well as the
release of proinflammatory cytokines and free fatty acids
[40, 41]. This, in turn, exacerbates chronic inflammation,
dyslipidemia, and insulin resistance [40, 41].
The effect of HIV on liver disease was well characterized
by Towner et al. in their case-control study which concluded
that HIV-infected individuals have a higher risk of hepatic
dysfunction and hepatic-related death compared to those
without HIV infection, even with adjustment for known
hepatic risk factors [42]. Marchetti et al. revealed that HIV
coinfected patients, mainly HCV, with higher TNF-𝛼 plasma
levels had a 13-fold increase in the risk of progression to a
Fib-4 > 1.45 [43]. However, these patients were not receiving
ART [43]. A more recent study suggests that ART with
good immune reconstitution can slow down liver fibrosis in
HIV/HCV coinfected patients [44].
3.3. Chronic Effects of cART. With the ever-emerging popu-
lation of patients with long-term controlled HIV infection,
the chronic effects of cART are becoming better understood.
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It has already been well established that a high proportion of
patients who delay cART until the CD4+ count drops below
200 cells/mm3 do not achieve a normal CD4+ count, even
after a decade of effective therapy [45]. In fact, the DHHS
guidelines now recommend usage of cART in all patients
regardless of CD4+ count [46]. Furthermore, studies have
suggested that CD4+ cell recovery from cART is both slower
and less pronounced in elderly patients, which provides
further credence to the concept that early cART initiationwill
lead to the best possible degree of immune regulation [47,
48]. These guidelines are supported by multiple randomized
controlled studies like START and TEMPRANOproving that
the earlier ART is started the better the immune system is
preserved and the less inflammation is present, with subse-
quently less mortality and morbidity [49, 50].
cARTmust also be considered a potential cause of adverse
events and, therefore, a possible contributor towards inflam-
mation and aging in those with controlledHIV infection [51].
Extra attention to drug toxicity from cART must be given to
the elderly HIV patient due to the high degree of concurrent
medication use and, thus, the greater potential for harmful
drug-drug interactions, as well as age-related changes in renal
and hepatic function that could affect drug clearance.
Certain regimens have been linked to toxicities that
increase the risk for comorbidities. This paper has already
mentioned the role of comorbidity in persistent inflamma-
tion. cART can further negatively contribute towards these
processes by augmenting the severity and effects of comorbid
conditions. Friis-Møller et al. studied the association between
cART and CVD risk factors and found that nonnucleo-
side reverse transcriptase inhibitor (NNRTI) and protease
inhibitor (PI) use was linked to elevated total cholesterol [52].
The D:A:D Study Group added further to this subject by
investigating the association between certain cARTdrugs and
acute myocardial infarction (AMI) [53]. The study revealed
that abacavir, didanosine, indinavir, and lopinavir-ritonavir
carried the most significant association [53]. Lang et al.
further contributed to this subject, stating that cumulative
exposure to PIs, especially (fos)amprenavir with or without
ritonavir and lopinavir with ritonavir, had increased risk for
AMI [54]. However, saquinavir was found not to have this
association [54]. Lopinavir and ritonavir were also shown to
increase the risk for AMI in a study conducted by Durand
et al. [55].
Abacavir increasing the risk for AMI has been a topic of
debate. A paper byMarcus et al. addressed this issue and con-
cluded that abacavir increases the risk of CVD by 2.2 times
[56]. Two other studies, one by the D:A:D group and another
by Obel et al., also confirmed that abacavir is associated with
AMI [57, 58]. In their cohort study, Choi et al. concluded that
recent abacavir exposure increased the risk for cardiovascular
events and that tenofovir (TDF) was associated with heart
failure [59]. Costagliola et al., however, reviewed the literature
on abacavir and CVD and reported that due to confounding
variables and selection bias, it is impossible to neither verify
nor repudiate a correlation between the two [60]. Many
studies claim that abacavir use carries no independent risk
for AMI [61–64]. Bedimo et al. found no association between
MI use and abacavir use but did report that abacavir use was
more common than TDF use in patients with chronic kidney
disease, which itself is an independent risk factor for CVD
[62]. Nonetheless, the DHHS guidelines suggest avoiding
abacavir and lopinavir/ritonavir in patients at high risk for
cardiovascular events [46].
Other associations between certain cART toxicities and
comorbidities have been established in the literature. Ryom
et al. found that cumulative use of stavudine, didanosine,
(fos)amprenavir, and TDFwas independently associatedwith
higher rates of end stage liver disease and hepatocellular
carcinoma [65]. In their prospective observational study,
De Wit et al. showed that stavudine and zidovudine were
linked with insulin resistance, perhaps due to toxic effects on
the mitochondria [66]. Moreover, TDF and efavirenz have
been linked with decreased bone marrow density [67]. In
their meta-analysis, Brown and Qaqish concluded that PI-
treated patients had increased odds of osteoporosis than
non-PI-treated patients [68]. Also, a study by Perrot et al.
linked TDF use to osteomalacia from proximal renal tubular
dysfunction [69]. Herlitz et al. further studied the potential
adverse events of TDF use by documenting reversible acute
tubular necrosis andmitochondrial dysmorphic changes in 13
cases of TDF-associated nephrotoxicity that were on therapy
for a mean of 19.6 months [70]. Two controlled, double-blind
phase 3 studies by Sax et al. compared the adverse events
associated with TDF with those of its newer formulation
tenofovir alafenamide (TAF) [71]. They concluded that TAF
has less renal and bone adverse events than TDF because this
tenofovir prodrug causes a 90% decrease in tenofovir plasma
concentration [71]. Also, TAFwas noninferior to TDF in sup-
pressing HIV VL [71]. Additionally, Leeansyah et al. studied
telomerase activity and length in vitro by looking at periph-
eral blood mononuclear cells (PBMCs) from HIV-infected
patients receiving aNRTI-containing regimen and found that
they had significantly lower telomerase activity than both
HIV-uninfected patients andHIV-infected patients receiving
a non-NRTI-containing regimen [72]. Telomerase length was
inversely associated with age, as well as the total duration
of NRTI-containing therapy [72]. This study concluded that
NRTIs at therapeutic concentrations, specifically TDF, inhibit
telomerase activity and this leads to its accelerated shortening
in activated PBMCs, which could play a role in the enhanced
aging of PLWH [72]. This is important because some studies
have reported that the HIV virus itself causes shortening
of leukocyte telomere length, and, therefore, TDF use may
further contribute towards this same process [73, 74].
3.4. Managing Inflammation in the HIV Patient. The man-
agement of cART in the HIV-infected patient must focus on
the need not only to suppress the serum HIV VL but also to
target potential viral reservoirs in order to decrease immune
activation and the chronic inflammatory response. One of
these possible reservoir sites is within the central nervous
system (CNS). In their CROI abstract, Anderson et al. exam-
ined the effect of cART therapy with good CNS penetration
in virally suppressed patients by documenting inflammatory
markers in cerebrospinal fluid (CSF) [75]. They found that,
during suppressive cART, regimens that are estimated to
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have better distribution into the CNS were associated with
decreased levels of CXCL10 and TNF-𝛼 within the CSF and,
therefore, less inflammation [75]. IL-6 remained elevated
even in regimens with good CNS penetration [75].
Another potential site for these reservoirs is within the
gut mucosa [76–78]. Gandhi et al. studied the effects of
adding another antiretroviral agent to an already suppressive
regimen [79]. They measured any changes in the level of
residual viremia in patients with VL < 20 copies/mL after
adding raltegravir (RAL) for 12 weeks [79]. They found that
intensification with RAL did not reduce the amount of resid-
ual viremia [79]. Although a study by Yukl et al. echoed the
same results for a RAL-containing intensification on the VL
in plasma, it did reveal a decrease in T-cell activation within
the gut [77]. Perhaps this is because RAL concentrations
remain significantly higher in the gut-associated lymphoid
tissue (GALT) and gastrointestinal tract than in the plasma,
causing less viral replication at these sites [78]. Hatano et al.
concurred with the observation that RAL intensification
decreases low-level viral replication, as evidenced by their
measurement of an increase in the level of 2-long terminal
repeat (2-LTR) circles in these patients [80]. Although this
is a promising treatment option, other accounts claim that
intensification with RAL did not increase overall CD4+ count
nor lower HIV proviral DNA in gut CD4+ cells [76].
Other studies have investigated changes in inflammatory
markers after switching suppressive cART to RAL [81–84].
The SPIRAL trial took controlled patients on a boosted pro-
tease inhibitor (PI) and then randomly switched them in a 1 : 1
fashion to RAL [82]. Results at 48 weeks after the randomized
switch revealed significant changes in several cardiovascular
biomarkers that could not be completely explained by lipid
changes [82]. Lake et al. reported a decrease in sCD14 in
obese women who were changed to RAL who previously
had controlled VL on a PI or NNRTI [84]. A study by Silva
et al. found a similar decrease in inflammatory markers in
virologically suppressed patients that were switched to RAL
from an enfuvirtide-based cART [83]. Lastly, Gupta et al.
changed patients virally suppressed on efavirenz to RAL and
documented that the switch group had decreased C-reactive
protein, sCD14, and renal function and increased levels of
sCD163 [85].This suggests that, compared to the continuation
group, RALmaymore positively impactmonocyte activation,
but it is not superior in its effects on endothelial function.
Furthermore, RAL could contribute more towards nephro-
toxicity than efavirenz [85].
Intensification with maraviroc (MVC) has also been
tested in virally suppressed patients to determine its effects
on CD4+ cell restoration and immune regulation. Cuzin et
al. added MVC for 24 weeks to the cART of 60 patients with
CD4+ < 350 cells/mm [86]. They found that these patients
were able to achieve an increase in CD4+ slopes [86]. Hunt
et al. also studied MVC intensification in patients with VL <
48 copies/mL and CD4+ < 350 cells/mm [87]. Compared
with the placebo group, MVC-treated subjects had increased
peripheral blood CD8+ cells, sCD14, and neutrophils, with
a lesser effect in suppressing CD4+ cell activation by week
24 [87]. Lastly, Belaunzara´n-Zamudio et al. compared the
immune recovery in patients with CD4+ < 100 cells/mmwho
received either MVC intensification or placebo to a standard
cART regimen [88]. Those on MVC retained higher rates of
CCR5+, CD4+, and CD8+ cells and had no effect on IRIS
occurrence [88].
There have been a small variety of head-to-head trials in
treatment na¨ıve patients in order to assess which regimens are
most efficacious in diminishing immune activation. Hileman
et al. examined markers of inflammation and monocyte
activation in a randomized controlled blinded study of single
tablet regimen of cobicistat/elvitegravir/emtricitabine/TDF
versus efavirenz/emtricitabine/TDF [89]. They concluded
that the elvitegravir-containing regimen had a greater
decrease in sCD14, hsCRP, and Lp-PLA2 levels compared
to the efavirenz-containing regimen [89]. The effects on the
inflammatory response by MVC versus TDF were examined
in an abstract submitted by Chan et al. [90]. They found that
initiating cARTwithMVC caused a greater increase in CD4+
cells, a smaller decrease in CD8+ cells, and a smaller increase
in CD4+/CD8+ ratio compared to TDF [90]. However, there
was no difference in changes in inflammatory biomarkers
between the two regimens [90]. Papakonstantinou et al. com-
pared the inflammatory effects on treatment na¨ıve patients
assigned a regimen of either TDF/emtricitabine/efavirenz or
abacavir/lamivudine/efavirenz [91]. The results of the study
revealed that the TDF-containing regimen caused a decrease
in platelet-activating factor (PAF) levels and lipoprotein-
associated phospholipase A2 (Lp-PLA2) activity [91]. The
abacavir-containing regimen showed no change in baseline
PAF and an increase in Lp-PLA2, whichmay be the reasoning
behind abacavir-associated cardiovascular adverse events
[91]. Lastly, Barrios et al. studied TDF + didanosine in
patients who were naı¨ve to treatment or who simplified a
prior suppressive cART regimen [92]. They established that
although VL was undetectable, a decline in CD4+ count was
evident, which they theorized could be due to an imbalance
in adenosine metabolites within CD4+ cells [92]. A summary
of the studies regarding cART intervention to manage the
chronic inflammatory state in HIV patients can be found in
Table 1.
There have also been promising studies suggesting alter-
nate therapies to treat chronic inflammation. Multiple pub-
lished trials revealed that rosuvastatin showed benefit in
reducing inflammation markers and immune activation [93–
95].Wooten at al. examined the effect of healthy diet and exer-
cise on inflammation in HIV patients with undetectable VL
and dyslipidemia [96]. They found that these interventions
effectively reduced plasma Lp-PLA2mass [96]. Furthermore,
patients should be counseled to stop smoking. Valiathan et al.
compared HIV-infected smokers and nonsmokers that had
documented viral suppression on cART to HIV-uninfected
smokers and nonsmokers [97].They found that smoking and
HIV infection both independently influence T-cell immune
activation and function, and together they present the worst
immune profile [97]. Villar-Garc´ıa et al. conducted a double-
blind, randomized, placebo-controlled trial of Saccharomyces
boulardii in 44 patients with viral load of <20 copies per
milliliter for at least 2 years. They found that this fungus
was very effective at decreasing microbial translocation and
inflammation parameters [98]. Another innovative approach
6 BioMed Research International
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at non-cART intervention was a 12-week, single-arm, open-
label study, whereby Sereti et al. tested the efficacy of IL-
7 adjunctive therapy on T-cell reconstitution in peripheral
blood and gut mucosa in 23 cART suppressed HIV-infected
patients with incomplete CD4+ recovery [99].They observed
that administration of r-hIL-7 improved the gut mucosal
abnormalities of chronic HIV infection and attenuated the
systemic inflammatory and coagulation abnormalities asso-
ciated with the said gut disease [99].
In the DHHS guidelines, the DHHS does not advo-
cate for cART intensification because this method has not
shown consistency in reducing the immune activation nor in
increasing T-cell recovery [46]. Furthermore, the guidelines
do not recommend switching cART regimens in virally
suppressed patients due to the lack of substantial evidence
of its effects on the chronic inflammatory response [46].
Also, no instructions for the trending of immune markers in
those with chronically suppressed HIV infection have been
incorporated into the guidelines because there has yet to be
any proven predictability value in morbidity and mortality
from doing so [46]. Because of this, the DHHS explains that
clinicians should aim at monitoring modifiable risk factors
for comorbid conditions [46]. Also, it is recommended that
patients with poor CD4+ recovery should be worked-up
for a modifiable cause, most notably adverse events from
medications [46].
4. Conclusion
Overall, the harmful effects of chronically suppressed HIV
infection on inflammation and immune activation must
always be considered when managing PLWH. As the pop-
ulation of HIV-infected patients ages, the long-term effects
of immune dysregulation will augment the severity of other
non-AIDS-related comorbidities. Furthermore, the potential
toxic events from certain cART could also contribute towards
increased morbidity and mortality compared to the general
population in the long run. Although knowledge about this
subject is increasing, real life data to suggest appropriate
ways to manage this inflammation related to HIV is seriously
lacking. There are not enough studies done to establish
a consensus to which antiretroviral drug class is best at
suppressing the inflammatory response. This is due to the
difficulty in finding the right means to accurately measure
the chronic inflammatory state. Clinicians will most likely
have to settle for a battery of tests that will be validated from
collectively trending them over time. At this point, a practical
approach to the management of PLWH to best preserve
the immune system and control the chronic inflammatory
process should be to (1) initiate cART as early as possible,
(2) both prevent and treat coinfection, (3) aggressively treat
any comorbid condition, (4) advise patients to stop smoking
and increase physical activity, and (5) switch cART to the
least toxic regimen. It is absolutely essential to conduct more
clinical trials to determine which regimens are both most
effective and safest at controlling the inflammatory response.
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